The Presence of Antibodies against a PF4-Heparin Complex in Patients on Haemodialysis

Thromb Haemost 1996; 76(03): 480
DOI: 10.1055/s-0038-1650607

Letters to the Editor

Schattauer GmbH Stuttgart

D M S Boon

The Departments of Hematology and Internal Medicine I, Rotterdam, The Netherlands

,

H H D M van Vliet

The Departments of Hematology and Internal Medicine I, Rotterdam, The Netherlands

,

R Zietse

The Departments of Hematology and Internal Medicine I, Rotterdam, The Netherlands

,

M C Kappers-Klunne

¹The University Hospital Rotterdam-Dijkzigt, Erasmus University, The Netherlands

References
1 Shelly MP, Majer RV, Perkins C, Pierce T, Nielsen MS. White clot syndrome and continuous arteriovenous haemofiltration. Intensive Care Med 1990; 16: 334-335
2 Greinacher A, Philippen KH, Kemkes-Matthes B, Möckl M, Mueller-Eck-hardt C, Schaefer K. Heparin-associated thrombocytopenia type II in a patient with end-stage renal disease; successful anticoagulation with the low-molecular-weight heparinoid Org 10172 during haemodialysis. Nephrol Dial Transplant 1993; 8: 1176-1177
3 Amiral J, Bridey F, Dreyfus M, Vissae AM, Fressinaud E, Wolf M, Meyer D. Platelet Factor 4 complexed to heparin is the target for antibodies generated in heparin induced thrombocytopenia. Thromb Haemost 1992; 68: 95-96
4 Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335